Verge Genomics

Company profile

About Verge Genomics

Verge Labs is a biotechnology company pioneering the application of frontier artificial intelligence to human biology, with a primary focus on neurological diseases. Over the past decade, the company has assembled one of the world's largest proprietary collections of multi-modal patient brain data, comprising deep molecular profiling on 12,000+ brains across 6,000+ patients. This dataset includes paired proteomic, genomic, and clinical data, plus a physical inventory of 900+ frozen brain tissue samples spanning major neurodegenerative diseases. The company has developed vBx-1.0, a breakthrough multi-modal foundation model for precision neurology that functions as a 'virtual biopsy' of the brain. This model can predict brain activity, therapy response, and side effects in patients with up to 3x greater accuracy than previous state-of-the-art models. By reconstructing what's happening inside a patient's brain from routine blood draws, the platform enables precision medicine approaches in neurology. Verge Labs' CONVERGE platform serves as an AI operating system for neuroscience drug development, addressing critical questions around target discovery, target characterization, biomarker identification, and patient stratification. The company has established $1.6B in partnerships with top-20 pharmaceutical companies and has advanced two AI-discovered drugs to clinical candidate stage, including VRG50635, which completed a Phase 1b trial in ALS in late 2025. The platform has surfaced 280+ novel drug targets with an 83% preclinical validation rate, demonstrating the power of starting drug discovery directly in human tissue rather than relying on animal models or cell culture systems.

Company description · Verge Genomics official website